Literature DB >> 3490587

Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS.

S Gartner, P Markovits, D M Markovitz, R F Betts, M Popovic.   

Abstract

Primary cultures from a brain biopsy specimen of a human T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) seropositive patient with progressive dementia contained small numbers of monocytoid cells and showed reverse transcriptase activity that persisted for as long as 100 days. Electron microscopy of these cells revealed the presence of HTLV-III/LAV virions. Subcultured cells removed from primary cultures by trypsinization were nonspecific esterase negative and did not express virus or show evidence of HTLV-III/LAV proviral sequences, while those remaining in the original flasks were nonspecific esterase positive and continued to produce virus. Virus from primary cultures was transmitted to peripheral blood-derived monocyte-macrophages and T cells. Virus production in T-cell cultures was transient while the monocyte-macrophages, like the primary cultures, produced virus for at least 120 days. Infection of several brain-derived cells with this and another HTLV-III/LAV isolate failed to demonstrate virus replication. These results indicate that the HTLV-III/LAV-infected cells recovered from the brain of this patient are cells of the mononuclear phagocyte series.

Entities:  

Mesh:

Year:  1986        PMID: 3490587

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  101 in total

1.  Activation of the human immunodeficiency virus type 1 enhancer is not dependent on NFAT-1.

Authors:  D M Markovitz; M C Hannibal; M J Smith; R Cossman; G J Nabel
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

2.  Human immunodeficiency virus and related retroviruses.

Authors:  R Nájera; M I Herrera; R de Andrés
Journal:  West J Med       Date:  1987-12

3.  Molecular characterization of biologically diverse envelope variants of human immunodeficiency virus type 1 derived from an individual.

Authors:  R S Daniels; M H Smith; A G Fisher
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

4.  Regulation of SIV mac 239 basal long terminal repeat activity and viral replication in macrophages: functional roles of two CCAAT/enhancer-binding protein beta sites in activation and interferon beta-mediated suppression.

Authors:  Shruthi Ravimohan; Lucio Gama; Sheila A Barber; Janice E Clements
Journal:  J Biol Chem       Date:  2009-11-20       Impact factor: 5.157

Review 5.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

6.  Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study.

Authors:  J M Orenstein; M S Meltzer; T Phipps; H E Gendelman
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

7.  Release of interleukin 1 inhibitory activity (contra-IL-1) by human monocyte-derived macrophages infected with human immunodeficiency virus in vitro and in vivo.

Authors:  R M Locksley; S Crowe; M D Sadick; F P Heinzel; K D Gardner; M S McGrath; J Mills
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

8.  HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies.

Authors:  Beau M Ances; David B Clifford
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

9.  Human immunodeficiency virus type 1 tropism for brain microglial cells is determined by a region of the env glycoprotein that also controls macrophage tropism.

Authors:  N E Sharpless; W A O'Brien; E Verdin; C V Kufta; I S Chen; M Dubois-Dalcq
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

10.  Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo.

Authors:  P Westervelt; D B Trowbridge; L G Epstein; B M Blumberg; Y Li; B H Hahn; G M Shaw; R W Price; L Ratner
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.